The results of the present study demonstrate that TLG-S criteria may help to better predict PFS and OS than other forms of assessment based on early FDG-PET response. Bone flares that can interfere with the interpretation of treatment response according to the PERCIST criteria are not uncommon in patients with metastatic lung adenocarcinoma treated with erlotinib. The high correlation between textural parameters and tumor volume limited the value of prognostic evaluation.
參考文獻
1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al.
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England journal of medicine.
2004;350:2129-39.
2. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. The Lancet Oncology. 2010;11:521-9.
3. van Gool MH, Aukema TS, Schaake EE, Rijna H, Valdes Olmos RA, van Pel R, et al. Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer. J Nucl Med. 2014;55:1081-6.
4. Hachemi M, Couturier O, Vervueren L, Fosse P, Lacoeuille F, Urban T, et al. [(1)(8)F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients. PloS one. 2014;9:e87629.
5. Schaake EE, Kappers I, Codrington HE, Valdes Olmos RA, Teertstra HJ, van Pel R, et al.
Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer. J Clin Oncol. 2012;30:2731-8.
6. Kobe C, Scheffler M, Holstein A, Zander T, Nogova L, Lammertsma AA, et al. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. Eur J Nucl Med Mol Imaging. 2012;39:1117-27.
7. Bengtsson T, Hicks RJ, Peterson A, Port RE. 18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value. J Nucl Med. 2012;53:530-7.
8. Zander T, Scheffler M, Nogova L, Kobe C, Engel-Riedel W, Hellmich M, et al. Early
prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol. 2011;29:1701-8.
9. Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, et al. Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non-Small Cell Lung Cancer Treated with Erlotinib. Clinical cancer research : an official journal of the American Association for Cancer Research.
2011;17:3304-15.
10. Binns DS, Pirzkall A, Yu W, Callahan J, Mileshkin L, Conti P, et al. Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011;38:642-50.
11. Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, et al. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med. 2011;52:1684-9.
12. Aukema TS, Kappers I, Olmos RA, Codrington HE, van Tinteren H, van Pel R, et al. Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer? J Nucl Med. 2010;51:1344-8.
13. van Gool MH, Aukema TS, Schaake EE, Rijna H, Codrington HE, Valdes Olmos RA, et al.
(18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer. Annals of surgical oncology.
2014;21:2831-7.
14. O'Brien ME, Myerson JS, Coward JI, Puglisi M, Trani L, Wotherspoon A, et al. A phase II study of (1)(8)F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks. Eur J Cancer.
2012;48:68-74.
15. Suleiman AA, Frechen S, Scheffler M, Zander T, Kahraman D, Kobe C, et al. Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib. J Thorac Oncol. 2015;10:84-92.
16. Kahraman D, Holstein A, Scheffler M, Zander T, Nogova L, Lammertsma AA, et al. Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic
differentiation in patients with advanced non-small cell lung cancer treated with erlotinib. Clin Nucl Med. 2012;37:1058-64.
17. de Langen AJ, van den Boogaart V, Lubberink M, Backes WH, Marcus JT, van Tinteren H, et al. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. J Nucl Med. 2011;52:48-55.
18. Cook GJ, O'Brien ME, Siddique M, Chicklore S, Loi HY, Sharma B, et al. Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of F-FDG Uptake at PET-Association with Treatment Response and Prognosis. Radiology. 2015;0:141309.
19. Winther-Larsen A, Fledelius J, Sorensen BS, Meldgaard P. Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib. Lung Cancer.
2016;94:81-7.
20. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al.
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Journal of Cancer. 1999;35:1773-82.
21. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. Journal of Nuclear Medicine.
2009;50:122S-50S.
22. Lind JSW, Postmus PE, Smit EF. Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report. Journal of Thoracic Oncology. 2010;5:554-7.
23. Chao HS, Chang CP, Chiu CH, Chu LS, Chen YM, Tsai CM. Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib. Clin Nucl Med. 2009;34:346-9.
24. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2009;15:4554-60.
25. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, et al.
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. British journal of cancer. 2008;99:923-9.
26. Takahashi K, Kohno T, Matsumoto S, Nakanishi Y, Arai Y, Yamamoto S, et al. Clonal and Parallel Evolution of Primary Lung Cancers and Their Metastases Revealed by Molecular Dissection of Cancer Cells. Clinical Cancer Research. 2007;13:111-20.
27. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer?
Nat Rev Cancer. 2012;12:323-34.
28. Stoecklein NH, Klein CA. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. International Journal of Cancer. 2010;126:589-98.
2009;9:302-12.
30. Chen ZY, Zhong WZ, Zhang XC, Su J, Yang XN, Chen ZH, et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. The oncologist. 2012;17:978-85.
31. Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJ. Quantifying tumour
heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging.
2013;40:133-40.
32. Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, et al. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med. 2013;54:19-26.
33. Hong R, Halama J, Bova D, Sethi A, Emami B. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning.
International journal of radiation oncology, biology, physics. 2007;67:720-6.
34. Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging: The Visual Response Score and the Change in Total Lesion Glycolysis. Clinical Positron Imaging. 1999;2:159-71.
35. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer. 2009;45:228-47.
36. Amadasun M, King R. Textural features corresponding to textural properties. Systems, Man and Cybernetics, IEEE Transactions on. 1989;19:1264-74.
37. Fang YH, Lin CY, Shih MJ, Wang HM, Ho TY, Liao CT, et al. Development and evaluation of an open-source software package "CGITA" for quantifying tumor heterogeneity with
molecular images. BioMed research international. 2014;2014:248505.
38. Ho KC, Fang YD, Chung HW, Liu YC, Chang JW, Hou MM, et al. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib. Eur J Nucl Med Mol Imaging. 2016;43:2155-65.
39. Fogelman I. The flare phenomenon: still learning after 35 years. European Journal of Nuclear Medicine and Molecular Imaging. 2011;38:5-6.
40. Krupitskaya Y, Eslamy HK, Nguyen DD, Kumar A, Wakelee HA. Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy. Journal of Thoracic Oncology. 2009;4:429-31.
41. Al-Nabhani K, Syed R, Haroon A, Almukhailed O, Bomanji J. Flare response versus disease progression in patients with non-small cell lung cancer. Journal of radiology case reports.
2012;6:34-42.
42. Jamal-Hanjani M, Quezada SA, Larkin J, Swanton C. Translational Implications of Tumor Heterogeneity. Clinical Cancer Research. 2015;21:1258-66.
43. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol. 2011;29:2972-7.
44. Vignot S, Frampton GM, Soria JC, Yelensky R, Commo F, Brambilla C, et al. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol. 2013;31:2167-72.
45. Thomas A, Rajan A, Lopez-Chavez A, Wang Y, Giaccone G. From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. Annals of Oncology.
2013;24:577-85.
46. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response
to gefitinib. Cancer science. 2008;99:929-35.
47. Orlhac F, Soussan M, Maisonobe J-A, Garcia CA, Vanderlinden B, Buvat I. Tumor Texture Analysis in 18F-FDG PET: Relationships Between Texture Parameters, Histogram Indices, Standardized Uptake Values, Metabolic Volumes, and Total Lesion Glycolysis. Journal of Nuclear Medicine. 2014;55:414-22.
48. Nyflot MJ, Yang F, Byrd D, Bowen SR, Sandison GA, Kinahan PE. Quantitative radiomics:
impact of stochastic effects on textural feature analysis implies the need for standards. Journal of medical imaging. 2015;2:041002.